Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The Drosophila melanogaster olfactory system ...
Health Canada grants authorization for Leqembi to treat early Alzheimer’s disease: Stockholm Tuesday, October 28, 2025, 10:00 Hrs [IST] BioArctic AB’s (publ) partner Eisai ann ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions ...
1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Abstract: The anomaly detection in photovoltaic (PV) cell electroluminescence (EL) image is of great significance for the vision-based fault diagnosis. Many researchers are committed to solving this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback